June 30, 2026
Advance Online

Advance Online
FDA approves ZORYVE® for Children 2 and Up
This is the first and only topical PDE4 inhibitor indicated for children as young as 2 years old.

This is the first and only topical PDE4 inhibitor indicated for children as young as 2 years old.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.